Opening up data at the European Medicines Agency
- 10 May 2011
- Vol. 342 (may10 1) , d2686
- https://doi.org/10.1136/bmj.d2686
Abstract
Widespread selective reporting of research results means we don’t know the true benefits and harms of prescribed drugs. Peter Gøtzsche and Anders Jørgensen describe their efforts to get access to unpublished trial reports from the European Medicines AgencyThis publication has 8 references indexed in Scilit:
- Outcome Reporting in Industry-Sponsored Trials of Gabapentin for Off-Label UseNew England Journal of Medicine, 2009
- Reporting Bias in Drug Trials Submitted to the Food and Drug Administration: Review of Publication and PresentationPLoS Medicine, 2008
- Selective Publication of Antidepressant Trials and Its Influence on Apparent EfficacyNew England Journal of Medicine, 2008
- Regulation of drugs for children in EuropeBMJ, 2007
- FDA is incapable of protecting US “against another Vioxx”BMJ, 2004
- Empirical Evidence for Selective Reporting of Outcomes in Randomized TrialsJAMA, 2004
- Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applicationsBMJ, 2003
- The effect of lorcainide on arrhythmias and survival in patients with acute myocardial infarction: an example of publication biasInternational Journal of Cardiology, 1993